Literature DB >> 15126176

Is adjustment of National Eye Institute Visual Function Questionnaire scores for general health necessary in randomized trials?

Päivi H Miskala1, Neil M Bressler, Curtis L Meinert.   

Abstract

PURPOSE: To assess whether treatment comparison of National Eye Institute Visual Function Questionnaire (NEI-VFQ) scores in a clinical trial is influenced by general health to warrant adjusting for it.
DESIGN: Two randomized pilot trials.
METHODS: Patients enrolled in two randomized pilot trials of submacular surgery versus observation for choroidal neovascularization had quality of life interviews (NEI-VFQ and the Short Form-36 Health Survey) 24 months after enrollment. Information on comorbidities was collected through chart reviews. Data from 120 patients were analyzed using linear regression methods.
RESULTS: Adjustment for comorbidities did not change the magnitude of the treatment effect on NEI-VFQ scores. However, adjustment for Short Form-36 physical and mental component summaries produced changes in the estimated treatment effect when NEI-VFQ scores were compared.
CONCLUSIONS: Adjustment of NEI-VFQ scores for general health may be advisable. The Short Form-36 summary scores may be appropriate for this purpose.

Entities:  

Mesh:

Year:  2004        PMID: 15126176     DOI: 10.1016/j.ajo.2003.11.018

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes.

Authors:  Yannis M Paulus; Joan L Jefferys; Barbara S Hawkins; Adrienne W Scott
Journal:  Qual Life Res       Date:  2017-03-29       Impact factor: 4.147

2.  Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12.

Authors:  Päivi H Miskala; Eric B Bass; Neil M Bressler; Ashley L Childs; Barbara S Hawkins; Carol M Mangione; Marta J Marsh
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

3.  SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration.

Authors:  Martijn S Visser; Sankha Amarakoon; Tom Missotten; Reinier Timman; Jan J Busschbach
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.